By Donna Loyle, communications specialist, LIMR
Main Line Health clinical researchers are recruiting patients who’ve been diagnosed with stage IV or recurrent squamous cell lung cancer and whose cancer cells test positive for the protein cMet. Researchers seek to determine the safety and effectiveness of the antibody medication telisotuzumab vedotin (ABBV-399), a drug currently being investigated to treat non-small cell lung cancer.
- Must have an IHC positive based on Ventana SP44 assay (H score ≥ 150).
- Must have progressed during or after prior platinum-based chemotherapy. For Stage I-III disease patients, progression on platinum-based chemotherapy must have occurred within one year from the last date patient received that therapy.
- Must not have peripheral edema > Grade 1 or peripheral neuropathy > Grade 1 at the time of sub-study registration.
- Must not have received prior treatment with cMet pathway inhibitors. And must not be taking strong CYP3A4 inhibitors within seven days prior to sub-study registration, nor plan to take while on protocol treatment and for 14 days after the last dose of study treatment.
Other eligibility criteria apply. Please visit the website for this trial for more information.
This trial (#S1400-K), which is part of the larger LUNG-MAP trial, is available at all Main Line Health acute care hospitals. Principal investigators are Albert DeNittis, MD, and Paul Gilman, MD. For more on this trial, visit https://www.mainlinehealth.org/research/clinical-trials/s1400-k.